Literature DB >> 28741271

Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.

Yoichiro Kitajima1,2, Hirokazu Takahashi1, Takumi Akiyama1, Kenichiro Murayama1, Shinji Iwane1, Takuya Kuwashiro1, Kenichi Tanaka1, Seiji Kawazoe3, Naofumi Ono2, Takahisa Eguchi2, Keizo Anzai1, Yuichiro Eguchi4.   

Abstract

BACKGROUND: Liver cirrhosis induces marked metabolic disorders, protein-energy malnutrition, and sarcopenia. The objective of the study reported here was to investigate the effects of dietary branched-chain amino acids (BCAAs) on systemic glucose metabolism, skeletal muscle, and prognosis of patients with liver cirrhosis.
METHODS: Japanese patients with liver cirrhosis (n = 21) were enrolled into a longitudinal study in which their diets were supplemented with BCAAs. We evaluated glucose metabolism and analyzed the skeletal muscle area index (SAI) and intramuscular adipose tissue content (IMAC) using computed tomography.
RESULTS: After 48 weeks of supplementation with BCAAs, there were no changes in glucose metabolism and skeletal muscle findings. In patients with ameliorated hypoalbuminemia, IMAC was significantly decreased and SAI was preserved concomitant with decreasing 90- and 120-min post-challenge plasma glucose levels (P < 0.01 each). In patients without increased albumin levels, IMAC was significantly increased and the SAI was significantly decreased (P < 0.01 each). Liver-related event-free survival rates for 72 months were 63.6% in patients with decreased IMAC and 20.0% in patients with increased IMAC.
CONCLUSIONS: Amelioration of hypoalbuminemia associated with BCAA supplementation correlated with decreased fat accumulation in skeletal muscle, maintenance of skeletal muscle mass, and improved glucose sensitivity, all factors which may contribute to improving the survival of patients with liver cirrhosis.

Entities:  

Keywords:  Branched-chain amino acids; Liver cirrhosis; Sarcopenia; Skeletal muscle steatosis

Mesh:

Substances:

Year:  2017        PMID: 28741271     DOI: 10.1007/s00535-017-1370-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

Review 1.  Hyperammonemia and proteostasis in cirrhosis.

Authors:  Srinivasan Dasarathy; Maria Hatzoglou
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-01       Impact factor: 4.294

2.  Association between low preoperative skeletal muscle quality and infectious complications following gastrectomy for gastric cancer.

Authors:  Tsuneyuki Uchida; Ryuichi Sekine; Kenichi Matsuo; Gaku Kigawa; Takahiro Umemoto; Kazuhiro Kijima; Yoshikuni Harada; Tetsuji Wakabayashi; Yuki Takahashi; Toshimitsu Shiozawa; Hideyuki Oyama; Shiori Shibata; Kuniya Tanaka
Journal:  Surg Today       Date:  2021-01-25       Impact factor: 2.549

Review 3.  Sarcopenia in chronic liver disease: mechanisms and countermeasures.

Authors:  Sophie L Allen; Jonathan I Quinlan; Amritpal Dhaliwal; Matthew J Armstrong; Ahmed M Elsharkawy; Carolyn A Greig; Janet M Lord; Gareth G Lavery; Leigh Breen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-11-25       Impact factor: 4.052

Review 4.  Branched-chain amino acids in liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-30

5.  Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

6.  Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study.

Authors:  Akitoshi Sano; Eiji Kakazu; Tatsuki Morosawa; Jun Inoue; Takayuki Kogure; Masashi Ninomiya; Tomoaki Iwata; Teruyuki Umetsu; Takuya Nakamura; Satoshi Takai; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-01-27       Impact factor: 7.527

Review 8.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

Review 9.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

10.  Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial.

Authors:  Tomomi Okubo; Masanori Atsukawa; Akihito Tsubota; Hiroki Ono; Tadamichi Kawano; Yuji Yoshida; Taeang Arai; Korenobu Hayama; Norio Itokawa; Chisa Kondo; Keiko Kaneko; Katsuhiko Iwakiri
Journal:  Nutrients       Date:  2021-05-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.